Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2018

View Archived Issues

Bioverativ conducts phase III trials with BIVV-009 in primary cold agglutinin disease

Green Cross LabCell and Feldan Therapeutics collaborate to develop NK cell immunotherapies

DNA repair-related biomarkers induced by alcohol have prognostic value in gastric cancer

The Salk Institute and Indivumed enter alliance to advance global cancer research

Tenax Therapeutics to develop levosimendan for PH-HFpEF

GigaGen awarded NIH grant to develop technology for rIVIG therapy

Centrexion Therapeutics' CNTX-4975 receives FDA fast track designation

ShangPharma Innovation enters multi-year strategic collaboration

Foundation Medicine, Pfizer partner to develop companion diagnostics

Jounce Therapeutics reviews its next-generation immunotherapy pipeline

U.S. priority review and E.U. accelerated assessment granted for Kymriah

FDA accepts Ruconest sBLA for review

Rxi Pharmaceuticals to focus on immuno-oncology

Gamida Cell commences phase I study of NAM-NK cells in NHL and MM

Context Therapeutics acquires Apristor from Arno Therapeutics

Final results reported from phase II study of Bekinda in IBS-D

AvantGen begins second cancer therapeutic antibody discovery program with Tanabe Research Labs

Abide Therapeutics gives an overview of their serine hydrolase-targeting products

Phase II LIBERTY study of ubenimex in PAH does not meet primary endpoint

Athenex gets positive feedback from FDA on phase III Oraxol study design

Zhejiang Palo Alto Pharmaceuticals divulges new NS5A inhibitors

FDA grants fast track designation to Aspyrian's RM-1929 in head and neck cancer

Almirall presents novel JAK inhibitors

Chinese reserachers disclose IDH1 inhibitors

Novel compounds for HBV presented by Roche

The Vanderbilt University divulges M4 receptor PAMs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...